Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) EBIT (2020 - 2025)

Lyell Immunopharma's EBIT history spans 5 years, with the latest figure at -$37.3 million for Q3 2025.

  • For Q3 2025, EBIT rose 26.24% year-over-year to -$37.3 million; the TTM value through Sep 2025 reached -$342.9 million, down 57.94%, while the annual FY2024 figure was -$358.8 million, 45.24% down from the prior year.
  • EBIT for Q3 2025 was -$37.3 million at Lyell Immunopharma, up from -$47.1 million in the prior quarter.
  • Across five years, EBIT topped out at -$14.8 million in Q4 2022 and bottomed at -$201.1 million in Q4 2024.
  • The 5-year median for EBIT is -$55.6 million (2024), against an average of -$60.5 million.
  • The largest annual shift saw EBIT surged 68.9% in 2022 before it plummeted 302.52% in 2023.
  • A 5-year view of EBIT shows it stood at -$47.5 million in 2021, then soared by 68.9% to -$14.8 million in 2022, then tumbled by 302.52% to -$59.5 million in 2023, then tumbled by 238.02% to -$201.1 million in 2024, then skyrocketed by 81.48% to -$37.3 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's EBIT are -$37.3 million (Q3 2025), -$47.1 million (Q2 2025), and -$57.4 million (Q1 2025).